Curetis and OpGen Enter Into Definitive Agreement to Combine Businesses Combined company creates a commercial-stage, transatlantic diagnostics company focusing on data-driven solutions for molecular ...

Curetis Expects Near-Term U.S. FDA Decision on 510(k) Clearance of Unyvero LRT for BAL Specimens European Investment Bank approves business combination transaction $9.4 million interim financing ...

ROCKVILLE, Md., May 16, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) today announced that the Company’s board of directors has approved a 1-for-10 reverse stock split ...

The OpGen Gene Panel product tests for causes of antimicrobial and antibiotic resistance in hospital patients. The FDA approval, CEO Oliver Schacht said, will help it move away from research and ...

GAITHERSBURG, Md., April 01, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat ...

ROCKVILLE, Md., April 29, 2024 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”) announced today that it entered into an agreement to sell its commercial customer contracts and ...

ROCKVILLE, Md., April 26, 2023 (GLOBE NEWSWIRE) -- OpGen (OPGN), Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and ...

OpGen ( (OPGN)) has provided an announcement. OpGen, Inc. appoints Mohd Azham Azudin as COO and Gillian Tan Rou Yee as Company Secretary, bringing extensive experience in private equity and corporate ...

Total revenue for 2022 was approximately $2.6 million Balance sheet strengthened by recently closed public offering with gross proceeds of $7.5 million Conference call to be held March 29, 2023 at ...